CLOs on the Move

Diabetes Centers of America

www.diabetesamerica.com

 
Diabetes Centers of America is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Mxe Inc

Mxe Inc is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Starr Regional Medical Center

Starr Regional Medical Center will be your trusted source online not only for your hospital information, but also for the time-saving, easy to use, in-depth healthcare information resource you`ll want to refer to frequently. Be active in your healthcare decisions, not a spectator. That`s why we give you access to millions of pages of the most credible, up-to-date medical information available. You can rely on such expert sources as The Merriam Webster Medical Dictionary.

Nu-Med Plus

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to concentrate on high growth potential markets where there are visible, distinct needs recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use.

NM Dept. of Health

The mission of New Mexico Department of Health is to promote health and wellness, improve health outcomes, and assure safety net services for all people in New Mexico.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.